参麦注射液对晚期癌症患者sIL－2R、LAK及NK细胞活性影响

本研究测定了６０例晚期癌症患者用参麦注射液治疗前后血清可溶性白细胞介素－２受体（ｓＩＬ－２Ｒ）、淋巴因子活化的杀伤细胞（ＬＡＫ）和天然杀伤细胞（ＮＫ）的活性，并以４０例正常人为对照。结果显示：治疗前癌症患者ｓＩＬ－２Ｒ显著升高（Ｐ＜０．０５），ＬＡＫ细胞与ＮＫ细胞活性显著减低（Ｐ＜０．０５）。而上述变化在胃癌、肠癌与肺癌之间无显著差异（Ｐ＞０．０５）。治疗后３种癌症患者的ｓＩＬ－２Ｒ均有显著下降（Ｐ＜０．０５），ＬＡＫ与ＮＫ细胞活性均有显著增强（Ｐ＜０．０５）。而ｓＩＬ－２Ｒ与ＬＫＡ及ＮＫ细胞活性之间无相关性。提示晚期癌症患者免疫功能低下，参麦注射液对癌症患者的免疫功能有广泛的调节作用。

英文摘要:

Serum interleukin-2 receptor(sIL-2R) level activities of natural killer cell(NK) and lymphokine activated killer cell(LAK) cells were determined in 60 patients with.advanced carcinoma(AC) before and after treatment with Shenmai injection(SMI),40 healthy persons were taken as non-carcinoma control(NC).The results showed that: Serum slL-2R level in AC were much higher than those in NC (p<0.05) and activities of NK and LAK cells in AC were much lower than those in NC(P<0.05)before treatment. There was no significant difference among gastric cancer,colonic carcinoma and lung cancer (P>0.05). After treatment with SMI we also found that the level of slL-2R in all patients were obviously lower (P<0.05) while the activity of NK and LAK cells were significantly higher than that prior treatment(p<0.05). Linear correlation was not found between slL-2R and NK, LAK cells.These data suggested that the immune function was compromised in AC. The mechanism of the inhibitory effect of SMI on carcinoma might be related to the activity of biological response modifier.

关闭